• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[肺腺癌免疫微环境特征与表皮生长因子受体突变状态的相关性]

[Correlation between Immune Microenvironment Features and EGFR Mutation Status 
in Lung Adenocarcinoma].

作者信息

Zhu Hongyu, Chen Peng, Dong Guozhang, Meng Fanchen, Xia Zhijun, You Jing, Kong Xiangru, Wu Jintao, Yuan Fangwei, Yu Xinyu, Sun Qinhong, Ji Jinfu, Wang Siwei, Liu Tongyan, Xu Lin

机构信息

Department of Thoracic Surgery, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu 
Institute of Cancer Research, Jiangsu Key Laboratory of Molecular and Translation Cancer Research, Nanjing 210009, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2023 Mar 20;26(3):204-216. doi: 10.3779/j.issn.1009-3419.2023.101.07.

DOI:10.3779/j.issn.1009-3419.2023.101.07
PMID:37035883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10106792/
Abstract

BACKGROUND

The morbidity and mortality rates of lung cancer remain high worldwide, and lung adenocarcinoma is one of the most important tissue subtypes of lung cancer. Epidermal growth factor receptor (EGFR) mutation is an important driver gene mutation for lung adenocarcinoma. In recent years, immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, have achieved remarkable efficacy in some lung cancer patients. Patients with EGFR mutations enjoyed limited benefits from immunotherapy according to recent studies. This study aimed to explore the relationship between EGFR mutation status and the spatial distribution as well as infiltration number of various immune cells in patients with EGFR mutant lung adenocarcinoma.

METHODS

This study included 62 lung adenocarcinoma patients who underwent surgery. Through multi-point sampling of surgically removed tumor tissues in different areas, 223 tumor tissue samples were finally obtained. We aquired EGFR mutations status including variant allele frequency (VAF) and mutation subtype in each tumor tissue by genetic test. Afterwards, hematoxylin-eosin (HE) staining, immunohistochemical staining and multiplex fluorescence immunohistochemistry staining have been performed, therefore the infiltration of various immune cells and the distribution of tertiary lymphoid structure (TLS) in tumor tissues were obtained by calculating the immunohistochemical score.

RESULTS

Compared with EGFR wild-type patients, patients with EGFR-mutant lung adenocarcinoma had more infiltration of CD68+ macrophages and major histocompatibility complex (MHC) class II antigen-presenting cells and higher spatial distribution heterogeneity of MHC class II antigen presenting cells in tumor tissues, while CD56+ natural killer cells and CD8+ T cells had lower infiltration. Tumor tissues with higher EGFR VAF were associated with lower cell infiltration such as CD3+ T cells, CD20+ B cells, CD56+ natural killer cells, CD68+ macrophages, CD8+ T cells, and only CD3+ T cells showed a lower spatial distribution heterogeneity. For the two common subtypes of EGFR mutations in Chinese population, tumor tissues with EGFR exon 19 deletion mutations have lower immune cell infiltration but higher spatial distribution heterogeneity of CD3+ T cells, CD56+ natural killer cells, CD68+ macrophages, and CD8+ T cells than that in EGFR exon 21 L858R mutant tumor tissues. Prognostic analysis found that patients with EGFR mutations with high degree of CD3+ T cells, CD20+ B cell infiltration and larger numbers of TLS formation and high spatial distribution heterogeneity of CD8+ T cell had longer disease-free survival.

CONCLUSIONS

EGFR-mutated lung adenocarcinoma had a unique "non-inflammatory" tumor microenvironment with low infiltration of immune cells, and there was also heterogeneity in the tumor microenvironment among the tumors with different mutation subtypes and mutation abundance. These differences were not only reflected in the number but also the spatial distribution of immune cell infiltration. Hence, further studies on the immune microenvironment of EGFR-mutant lung adenocarcinoma were of great significance for improving the efficacy of immunotherapy in EGFR-mutant lung adenocarcinoma patients in the future.

摘要

背景

肺癌的发病率和死亡率在全球范围内仍然很高,肺腺癌是肺癌最重要的组织学亚型之一。表皮生长因子受体(EGFR)突变是肺腺癌的重要驱动基因突变。近年来,免疫检查点抑制剂(ICI),如程序性细胞死亡蛋白1(PD-1)和程序性细胞死亡配体1(PD-L1)抑制剂,在一些肺癌患者中取得了显著疗效。根据最近的研究,EGFR突变患者从免疫治疗中获益有限。本研究旨在探讨EGFR突变状态与EGFR突变型肺腺癌患者各种免疫细胞的空间分布及浸润数量之间的关系。

方法

本研究纳入62例接受手术的肺腺癌患者。通过对手术切除的肿瘤组织进行不同区域的多点采样,最终获得223个肿瘤组织样本。我们通过基因检测获得每个肿瘤组织的EGFR突变状态,包括变异等位基因频率(VAF)和突变亚型。之后,进行苏木精-伊红(HE)染色、免疫组织化学染色和多重荧光免疫组织化学染色,通过计算免疫组织化学评分获得肿瘤组织中各种免疫细胞的浸润情况和三级淋巴结构(TLS)的分布。

结果

与EGFR野生型患者相比,EGFR突变型肺腺癌患者的肿瘤组织中CD68+巨噬细胞和主要组织相容性复合体(MHC)II类抗原呈递细胞浸润更多,MHC II类抗原呈递细胞的空间分布异质性更高,而CD56+自然杀伤细胞和CD8+T细胞浸润较低。EGFR VAF较高的肿瘤组织与较低的细胞浸润相关,如CD3+T细胞、CD20+B细胞、CD56+自然杀伤细胞、CD68+巨噬细胞、CD8+T细胞,只有CD3+T细胞表现出较低的空间分布异质性。对于中国人群中两种常见的EGFR突变亚型,与EGFR外显子21 L858R突变肿瘤组织相比,EGFR外显子19缺失突变的肿瘤组织免疫细胞浸润较低,但CD3+T细胞、CD56+自然杀伤细胞、CD68+巨噬细胞和CD8+T细胞的空间分布异质性较高。预后分析发现,CD3+T细胞、CD20+B细胞浸润程度高、TLS形成数量多且CD8+T细胞空间分布异质性高的EGFR突变患者无病生存期更长。

结论

EGFR突变型肺腺癌具有独特的“非炎症性”肿瘤微环境,免疫细胞浸润低,不同突变亚型和突变丰度的肿瘤之间肿瘤微环境也存在异质性。这些差异不仅体现在免疫细胞浸润的数量上,还体现在空间分布上。因此,进一步研究EGFR突变型肺腺癌的免疫微环境对于未来提高EGFR突变型肺腺癌患者的免疫治疗疗效具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/62a222c3714a/zgfazz-26-3-204-img_8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/801e0d66e305/zgfazz-26-3-204-img_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/128360875d8b/zgfazz-26-3-204-img_2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/c136b9db17ff/zgfazz-26-3-204-img_3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/27be50967c05/zgfazz-26-3-204-img_4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/e6cee04f0c4e/zgfazz-26-3-204-img_5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/c73198a9b959/zgfazz-26-3-204-img_6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/77c719f316a8/zgfazz-26-3-204-img_7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/62a222c3714a/zgfazz-26-3-204-img_8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/801e0d66e305/zgfazz-26-3-204-img_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/128360875d8b/zgfazz-26-3-204-img_2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/c136b9db17ff/zgfazz-26-3-204-img_3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/27be50967c05/zgfazz-26-3-204-img_4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/e6cee04f0c4e/zgfazz-26-3-204-img_5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/c73198a9b959/zgfazz-26-3-204-img_6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/77c719f316a8/zgfazz-26-3-204-img_7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c25/10106792/62a222c3714a/zgfazz-26-3-204-img_8.jpg

相似文献

1
[Correlation between Immune Microenvironment Features and EGFR Mutation Status 
in Lung Adenocarcinoma].[肺腺癌免疫微环境特征与表皮生长因子受体突变状态的相关性]
Zhongguo Fei Ai Za Zhi. 2023 Mar 20;26(3):204-216. doi: 10.3779/j.issn.1009-3419.2023.101.07.
2
[Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].基于TCGA数据库的EGFR突变型与EGFR野生型肺腺癌患者免疫微环境比较研究
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):236-244. doi: 10.3779/j.issn.1009-3419.2021.102.15.
3
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.罕见 EGFR 突变型非小细胞肺癌患者的 PD-L1 表达和 T 细胞浸润与免疫治疗反应。
Lung Cancer. 2020 Apr;142:98-105. doi: 10.1016/j.lungcan.2020.02.010. Epub 2020 Feb 19.
4
Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.同步性多原发肺癌的基因组图谱及其与 TMB、PD-L1 表达和免疫细胞浸润图谱的关联。
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003773.
5
The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.中国 EGFR/ALK 野生型肺腺癌患者中基因组改变与 PD-L1 表达的相关性及 Hippo 通路突变对免疫治疗的潜在预测价值。
Cancer Med. 2024 Feb;13(3):e7038. doi: 10.1002/cam4.7038.
6
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.抗 PD-1/PD-L1 免疫疗法疗效的分子异质性与东亚非小细胞肺癌患者的肿瘤免疫微环境相关。
Cancer Biol Med. 2020 Aug 15;17(3):768-781. doi: 10.20892/j.issn.2095-3941.2020.0121.
7
Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.单细胞转录组分析揭示了 EGFR 突变型肺腺癌中抑制性的肿瘤免疫微环境。
J Immunother Cancer. 2022 Jan;10(2). doi: 10.1136/jitc-2021-003534.
8
Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.非小细胞肺癌原发肿瘤与脑转移瘤之间肿瘤免疫微环境的时空异质性。
BMC Cancer. 2024 Jan 24;24(1):123. doi: 10.1186/s12885-024-11875-w.
9
Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.具有 ALK 重排突变的非小细胞肺癌患者的免疫微环境特征及其临床意义。
Front Immunol. 2022 Sep 8;13:974581. doi: 10.3389/fimmu.2022.974581. eCollection 2022.
10
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.PD-L1 表达和 CD8+T 细胞浸润在 EGFR 突变和 ALK 重排肺癌患者中的临床意义。
Lung Cancer. 2018 Nov;125:86-92. doi: 10.1016/j.lungcan.2018.09.010. Epub 2018 Sep 14.

引用本文的文献

1
The role of B cell immunity in lung adenocarcinoma.B细胞免疫在肺腺癌中的作用。
Genes Immun. 2025 May 13. doi: 10.1038/s41435-025-00331-9.
2
Synergistic Anti-Tumor Efficacy Achieved by Reversing Drug Resistance through the Regulation of the Tumor Immune Microenvironment with IL-12 and Osimertinib Combination Therapy.通过IL-12与奥希替尼联合治疗调节肿瘤免疫微环境逆转耐药性实现协同抗肿瘤疗效。
J Cancer. 2024 Jun 17;15(14):4534-4550. doi: 10.7150/jca.95407. eCollection 2024.

本文引用的文献

1
Cancer incidence and mortality in China, 2015.2015年中国的癌症发病率和死亡率
J Natl Cancer Cent. 2020 Dec 17;1(1):2-11. doi: 10.1016/j.jncc.2020.12.001. eCollection 2021 Mar.
2
Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects.表皮生长因子受体突变型晚期非小细胞肺癌的免疫治疗:现状、可能机制与应用前景。
Front Immunol. 2022 Jul 22;13:940288. doi: 10.3389/fimmu.2022.940288. eCollection 2022.
3
Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
单细胞转录组分析揭示了 EGFR 突变型肺腺癌中抑制性的肿瘤免疫微环境。
J Immunother Cancer. 2022 Jan;10(2). doi: 10.1136/jitc-2021-003534.
4
Role of Immune Checkpoint Inhibitor Therapy in Advanced -Mutant Non-Small Cell Lung Cancer.免疫检查点抑制剂疗法在晚期突变型非小细胞肺癌中的作用
Front Oncol. 2021 Nov 16;11:751209. doi: 10.3389/fonc.2021.751209. eCollection 2021.
5
[Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].基于TCGA数据库的EGFR突变型与EGFR野生型肺腺癌患者免疫微环境比较研究
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):236-244. doi: 10.3779/j.issn.1009-3419.2021.102.15.
6
The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy.表皮生长因子受体(EGFR)突变的非小细胞肺癌(NSCLC)患者中变异等位基因频率对靶向治疗的影响
Front Oncol. 2021 Mar 30;11:644472. doi: 10.3389/fonc.2021.644472. eCollection 2021.
7
EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study.表皮生长因子受体(EGFR)变异等位基因频率预测肺腺癌中EGFR酪氨酸激酶抑制剂(EGFR-TKI)的疗效:一项多中心研究。
Transl Lung Cancer Res. 2021 Feb;10(2):662-674. doi: 10.21037/tlcr-20-814.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
Uncommon mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors.肺腺癌中的罕见突变:特征及对酪氨酸激酶抑制剂的反应
J Thorac Dis. 2020 Sep;12(9):4643-4650. doi: 10.21037/jtd-19-3790.
10
Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy.癌症免疫治疗时代的多重免疫组化/免疫荧光技术概述。
Cancer Commun (Lond). 2020 Apr;40(4):135-153. doi: 10.1002/cac2.12023. Epub 2020 Apr 17.